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Abstract
Although primary toxoplasmosis is a rare event follow-
ing kidney transplantation, it can be life threatening.
This report describes this complication. The patient pre-
sented with high-grade fever, haemolytic anaemia and
haemophagocytic-syndrome-related pancytopaenia. Toxo-
plasma gondii diagnosis was ascertained by blood and
bone-marrow PCR assays. After 6 weeks with Clin-
damycin plus pyrimethamine therapies and despite nega-
tivation of T. gondii blood PCR assay, the patient developed
left-ventricular failure. After adding sulfamethoxazole/
trimethoprim, ramipril, digoxine, bisoprolol and spirono-
lactone, he progressively recovered. Anti-T. gondii therapy
was continued for 6 months. Four years later he received a
third kidney allograft: at that time anti-T. gondii antibodies
had become negative. The outcome was uneventful despite
immunosuppression but with inclusion of sulfamethoxa-
zole/trimethoprim prophylaxis. More than 3 years after the
third kidney transplantation the patient has had no toxo-
plasmosis reactivation. This case report highlights that T.
gondii can be the cause of myocarditis in a renal transplant
recipient.
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Toxoplasmosis is a worldwide infectious disease caused
by the protozoan Toxoplasma gondii. The disease has a
favourable outcome in almost all immunocompetent in-
dividuals, whereas it can be life threatening in those who
areimmunocompromised,suchasorgan-transplantpatients
[1].Inthelattersetting,thediseasecanresultfromT.gondii
transmission either within the allograft from a seropositive
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donor into a seronegative recipient [2–4] or via blood [5]
from immunocompetent donors. In organ-transplant recip-
ients, the most usual mechanism is the reactivation of la-
tent infection in the recipient [1]. In immunocompromised
patients, toxoplasmosis can present as central nervous sys-
tem (CNS)-related symptoms, chorioretinitis, pneumonitis
or multiorgan involvement, presenting with acute respira-
tory failure or haemodynamic abnormalities similar to sep-
tic shock [1]. T. gondii-related haemophagocytic syndrome
has also been reported [6,7] as well as T. gondii-related
haemolytic anaemia [8–11]. In heart-transplant recipients
who are T. gondii seronegative and who receive a T. gondii
seropositive allograft, primary toxoplasmosis can present
as myocarditis or cardiomyopathy [12]. A case of an un-
usual presentation of primary toxoplasmosis complicated
by a probable toxoplasmosis-induced acute left-ventricular
heart failure in a patient with failed renal allograft is
reported.
Case report
A male patient, born in 1982, had bilateral congenital kid-
ney hypoplasia and underwent a first kidney transplant,
from a living donor, in 1984, and did not experience acute
rejection. Immunosuppression consisted of cyclosporine,
steroids, plus azathioprine (AZA) until 1989. At this point
he lost his allograft due to chronic rejection. A second
kidney transplantation, from a deceased donor, was per-
formed in 1990. At that time his toxoplasmosis serology
was negative. Immunosuppression included induction ther-
apy with antithymocyte globulins, AZA, steroids and cy-
closporine,withoutmethylprednisolonepulses.Heprogres-
sively developed chronic allograft nephropathy in 2000
and cyclosporine was replaced by tacrolimus, and AZA
by mycophenolate mofetil (MMF). In the spring of 2001,
his serum creatinine was 522 µmol/L, i.e. calculated cre-
atinine clearance (Cockcroft–Gault formula) was 16 mL/
min. The immunosuppression was based on tacrolimus
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(4 mg/day, i.e. trough levels of 5 ng/mL), MMF (1 g/day)
and prednisolone (0.19 mg/kg/day). In June 2001, daily
hyperthermia (above 39◦C), maculo-papular skin erup-
tions, diarrhoea, vomiting and weight loss (−10% within
2 weeks) developed and he was admitted in our unit.
The body temperature was 39◦C, blood pressure was 150/
85 mmHg, with regular pulse at 100/bpm and no oedema
was noted. A biological work-up revealed a serum crea-
tinine of 1077 µmol/L and BUN of 43 mmol/L. He had
haemolytic anaemia: haemoglobin was 7.8 g/dL, the reticu-
locyte count was 85 000/mm3, and a low haptoglobin level
(<0.06 g/L) and high lactate dehydrogenase (4500 IU/
L; N < 500) were found. Schistocytes, antinuclear au-
toantibodies and a Coomb’s test were all negative. Platelet
count was 105 000/mm3 and leucopaenia was 900/mm3,o f
which 315 were polymorphonuclear cells. A bone-marrow
aspiration disclosed increased cellular density, associated
with features of haemophagocytic syndrome. Blood was
assessed for viraemias by PCR. Cytomegalovirus (CMV),
Epstein–Barr virus, herpes simplex type 6 virus and par-
vovirus B19 were negative while CMV and hepatitis serol-
ogy were also negative. He did have protective antibodies
against hepatitis B virus (anti-HBs). Blood, urine, stool
and bone-marrow cultures were negative for bacteria and
fungi. Conversely, blood and bone-marrow samples, as-
sessed by PCR, were positive for T. gondii. Serology test-
ing with an immuno-enzymatic method (AXSYM, Abbott
Laboratories, UK) found specific T. gondii IgM (index
0.94; N < 0.6) without specific IgG, whereas 1 month
earlier T. gondii serology had been negative. A central ner-
vous system (CNS) computed tomography was normal,
and the CNS fluid examination was negative for bacte-
ria, viruses, fungi and parasites, including T. gondii (as
assessed by PCR). At that time, no transthoracic echocar-
diogram was performed. Because of the allograft failure,
thepatientwasplacedondailyhaemodialysisforthreecon-
secutive days, and then scheduled for sessions lasting 4 h,
three times a week. Tacrolimus and MMF therapy were
stopped,whereasprednisolonewascontinued.Becausepri-
marytoxoplasmosisdiagnosishadbeenconfirmed,therapy
with clindamycin (2 g/day) and pyrimethamine (50 mg/
day) plus folinic acid was initiated. He was discharged
21 days after initial admission with a temperature of 38◦C,
blood pressure of 145/85 mmHg and a regular heart rate
at 110/bpm. White blood cell and platelet counts were nor-
mal, whereas he still had haemolytic anaemia (Hb 9.7 g/dL,
reticulocytesof229000/mm3 andhaptoglobinof0.06g/L).
The C-reactive protein was 9.7 mg/L. The toxoplasmo-
sis blood PCR test had become negative, whereas toxo-
plasmosis serology still demonstrated both specific IgM
and IgG. Six weeks after anti-toxoplasmosis treatment
had been initiated the patient complained of severe dys-
pnoea [grade III (NYHA classification)], which was not
improved by the dialysis sessions. His blood pressure was
low at 100/70 mmHg. An electrocardiogram showed si-
nusal tachycardia at 140 bpm. A chest radiograph showed
the heart area to be enlarged and a transthoracic echocar-
diogram showed a hypokinetic left ventricle with an ejec-
tion fraction of 10%; the right ventricle was not dilated.
There was no evidence of pulmonary hypertension. These
findings were confirmed by two different operators. Iso-
topic left ventriculography estimated the left ventricular
ejection fraction to be 20%. The 24-h cardiac rhythm data
displayed no abnormalities. The VO2-max was measured
to be 12 mL/kg/min. A percutaneous angiocoronarogra-
phy was normal. The patient declined an endomyocardic
biopsy. Selenium as well as vitamin B1 plasma levels
were within the normal ranges. The work-up for infections
(bacterial, viral, fungal, parasitical) was negative, apart
from an increase in the anti-T. gondii IgM and IgG titres.
A repeated blood PCR test for toxoplasmosis remained
negative. In addition to Clindamycin and pyrimethamine,
sulfamethoxazole/trimethoprim at a dose of 800/120 mg
given after each dialysis sessions, ramipril 2.5 mg/day,
digoxine three tablets per week, bisoprolol 1.25 mg/
day and spironolactone 25 mg/day were added. Finally,
the patient was placed on a heart-transplant waiting list.
Cardiac function remained poor within the following
month but had improved by 2 months later (by Novem-
ber 2001), with a left ventricular ejection fraction of
47% (at which point he was removed from the heart-
transplant waiting list). The ejection fraction further in-
creased to 60% by October 2002. Anti-toxoplasmosis ther-
apy was given for a total of 6 months. In March 2005,
the patient underwent a successful third kidney trans-
plantation: at this point the toxoplasmosis serology had
became negative. He received a T-cell depleting ther-
apy, i.e. antithymocyte globulins, tacrolimus, MMF and
steroids. In addition, he also received toxoplasmosis pro-
phylaxis with sulfamethoxazole/trimethoprim (400/80 mg
every other day) for 1 year. More than 3 years after his
third kidney transplantation no toxoplasmosis reactivation
occurred and the serum creatinine was 130 µmol/L.
Discussion
Toxoplasmosis infection is considered to be rare after kid-
ney transplantation. A retrospective survey of 657 con-
secutive kidney-transplant patients, from 2001 to 2005,
revealed only one single case of clinical toxoplasmosis, oc-
curring in an otherwise immunized patient [13]. Iqbal et al.
[14] found that only 33.1% of patients had antibodies
against T. gondii before transplantation. Within the first
year posttransplantation, however, 19 seronegative patients
out of 111 seroconverted for T. gondii. Of these, none de-
velopedclinicaltoxoplasmosis.Intheseropositivepatients,
34 out of 49 patients had an increase in T. gondii antibod-
ies, although none developed toxoplasmosis [14]. In a re-
view article,Renoult etal. reportedon 29kidney transplant
patients with posttransplant toxoplasmosis: this originated
from the donor in 10 cases; the mortality rate was as high
as 64.5% [15].
In kidney-transplant patients toxoplasmosis can be asso-
ciated in rare cases with haemophagocytic-related pancy-
topaenia [6,7]. This situation can be life threatening; the
diagnosis is based on a bone-marrow aspiration, which can
sometimesfindtachyzoitesthatarepathognomonicfortox-
oplasmosis. Blood and bone-marrow PCR tests are also of
value in rapidly detecting T. gondii infections in these cir-
cumstances [16], and is now the most sensitive method.
Toxoplasmosis has also been associated with haemolyticToxoplasmosis after kidney transplantation 431
anaemia [8–11], though its mechanisms are still poorly
understood. Our patient had previously received high
amounts of immunosuppressive therapy and two kidney
transplants, thus totalling 16 years of immunosuppres-
sive therapy plus an induction therapy with antithymocyte
globulins. He presented with both haemophagocytic and
haemolytic syndromes and 6 weeks after the start of clin-
damycin and pyrimethamine he presented with myocardi-
tis. Myocarditis can be suspected from symptoms of fever,
sudden onset of global heart failure and biventricular hy-
pokinesia. He fulfilled these three criteria, except that ven-
tricular hypokinesia was located only in the left chamber.
No other cause for myocarditis was found. Although we
could not directly demonstrate that the myocarditis was re-
lated to primary toxoplasmosis infection, we strongly sus-
pected a toxoplasmosis-induced myocarditis based on the
recent medical history of the patient, the increase in the
anti-T. gondii IgM and IgG titres and the improvement af-
ter sulfamethoxazole/trimethoprim therapy had been added
to previous therapies. A confirmation by endomyocardial
biopsy [17] was not possible. At that time, his blood PCR
test for toxoplasmosis was negative, which is not surprising
because the parasite, i.e. tachyzoites, can only be detected
during the transient parasitaemic phase. After the phase,
the parasite forms cysts within the tissues that can only be
detected by a biopsy. Tachyzoites are disseminated via the
bloodstream and infect many tissues, including the CNS,
eye and skeletal and heart muscles. We can speculate that
T. gondii may persist in the myocardium even though it is
not detected in the blood. Our case report highlights how
a patient with a failed allograft can present with the same
infectious complication as a transplant patient receiving a
high immunosuppressive regimen. Mariani et al. [18] re-
ported a complete atrioventricular block associated with
toxoplasmosis myocarditis, but in this case, toxoplasmosis-
induced myocarditis diagnosis was based only on positive
anti-T. gondii IgM and IgG, and neither the blood PCR test
nor the endomyocardial biopsy was performed.




T. gondii seropositivity is associated with an increased risk
of all-cause and cardiac mortality, with an increase in the
development of advanced cardiac allograft vasculopathy
[20]. The risk of toxoplasmosis in heart-transplant recip-
ients can be decreased by prophylaxis [21–23]. In human
immunodeficiency virus (HIV)-positive patients before the
era of antiretroviral therapy, a series of necropsies in 182
HIV patients found cardiac toxoplasmosis in 12% (n =
21), of whom one out of seven cases were not associated
with CNS involvement. However, in these 21 patients, car-
diac toxoplasmosis was suspected in only three [24]. After
kidney transplantation, so far, only one case of T. gondii-
related myocarditis has been reported in a patient who had
T. gondii-related encephalitis; however, this diagnosis was
established on postmortem analysis [25].
In immunocompromised patients, the most frequently
used successful regimen for toxoplasmosis is a combina-
tion of pyrimethamine/sulfadiazine and folinic acid for 4–
6 weeks; in HIV patients sulfamethoxazole/trimethoprim
appears to be equivalent to the latter regimen [1]. In our
patient, we initially replaced sulfadiazine with clindamycin
becausehepresentedwithend-stagekidneydiseasebecause
of his failing renal allograft. After 1 month of this ther-
apy he developed cardiac failure, which demonstrates that
our therapeutic choice was probably insufficient, but the
addition of sulfamethoxazole/trimethoprim therapy rapidly
improved the patient’s clinical situation.
Regarding T. gondii prophylaxis, kidney-transplant pa-
tients usually receive sulfamethoxazole/trimethoprim as
prophylaxis for Pneumocystis jiroveci within the first
6 months posttransplantation and this prophylaxis also pre-
vents toxoplasmosis. After that period, only those who
have low TCD4 lymphocyte counts and are at risk for T.
gondii, i.e. donor (+)/recipient (−), should be considered
for subsequent T. gondii screening and possible long-term
prophylaxis.
We conclude that primary toxoplasmosis in kidney-
transplant patients can be life-threatening, particularly
when complicated by haemophagocytic syndrome and
acute left-ventricular heart failure.
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